Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative Journal Articles uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • Abstract Background Predicting the risk of recurrence and response to chemotherapy in women with early breast cancer is crucial to optimise adjuvant treatment. Despite the common practice of using multigene tests to predict recurrence, existing recommendations are inconsistent. Our aim was to formulate healthcare recommendations for the question “Should multigene tests be used in women who have early invasive breast cancer, hormone receptor-positive, HER2-negative, to guide the use of adjuvant chemotherapy?” Methods The European Commission Initiative on Breast Cancer (ECIBC) Guidelines Development Group (GDG), a multidisciplinary guideline panel including experts and three patients, developed recommendations informed by systematic reviews of the evidence. Grading of Recommendations Assessment, Development and Evaluation (GRADE) Evidence to Decision frameworks were used. Four multigene tests were evaluated: the 21-gene recurrence score (21-RS), the 70-gene signature (70-GS), the PAM50 risk of recurrence score (PAM50-RORS), and the 12-gene molecular score (12-MS). Results Five studies (2 marker-based design RCTs, two treatment interaction design RCTs and 1 pooled individual data analysis from observational studies) were included; no eligible studies on PAM50-RORS or 12-MS were identified and the GDG did not formulate recommendations for these tests. Conclusions The ECIBC GDG suggests the use of the 21-RS for lymph node-negative women (conditional recommendation, very low certainty of evidence), recognising that benefits are probably larger in women at high risk of recurrence based on clinical characteristics. The ECIBC GDG suggests the use of the 70-GS for women at high clinical risk (conditional recommendation, low certainty of evidence), and recommends not using 70-GS in women at low clinical risk (strong recommendation, low certainty of evidence).


  • Giorgi Rossi, Paolo
  • Lebeau, Annette
  • Canelo-Aybar, Carlos
  • Saz-Parkinson, Zuleika
  • Quinn, Cecily
  • Langendam, Miranda
  • Mcgarrigle, Helen
  • Warman, Sue
  • Rigau, David
  • Alonso-Coello, Pablo
  • Broeders, Mireille
  • Graewingholt, Axel
  • Posso, Margarita
  • Duffy, Stephen
  • Schunemann, Holger
  • Autelitano, Mariangela
  • Borisch, Bettina
  • Castells, Xavier
  • Colzani, Edoardo
  • Daneš, Jan
  • Fitzpatrick, Patricia
  • Giordano, Livia
  • Hofvind, Solveig
  • Ioannidou-Mouzaka, Lydia
  • Knox, Susan
  • Nystrom, Lennarth
  • Parmelli, Elena
  • Perez, Elsa
  • Torresin, Alberto
  • Van Engen, Ruben
  • Van Landsveld-Verhoeven, Cary
  • Young, Ken

publication date

  • April 27, 2021

has subject area